Beyond imaging and genetic testing, several distinct lines of research reported in 2026 are reshaping how doctors think about high-risk localized prostate cancer, hard-to-treat metastatic disease, and even how long treatment needs to continue once it’s working. Here’s a look at four developments getting attention from researchers this year.
Treating around surgery, not just after it: the PROTEUS trial
For men with high-risk localized prostate cancer undergoing surgery, the standard approach has generally been hormone therapy paired with the operation itself. The Phase III PROTEUS trial tested something different: adding the drug apalutamide, an androgen-blocking therapy, both before and after surgery in roughly 2,100 men with high-risk disease, on top of standard hormone therapy.
The results, published in the New England Journal of Medicine and presented at ASCO 2026, showed that this perioperative intensification led to a 20% lower risk of cancer spreading and a longer time before patients needed additional treatment, compared with surgery and hormone therapy alone. It’s an example of a broader trend in prostate cancer research: treating the window around a major procedure as an opportunity, not just a formality.
A biomarker-driven approach for PTEN-deficient disease
Not all prostate cancers are alike at the molecular level, and one gene loss in particular — PTEN — has been linked to more aggressive, treatment-resistant disease. The CAPItello-281 trial examined whether targeting this vulnerability directly could help. In men with metastatic hormone-sensitive prostate cancer whose tumors showed significant PTEN loss, adding the drug capivasertib improved radiographic progression-free survival by 7.5 months compared with standard therapy.
Researchers were candid that an overall survival benefit hasn’t yet been demonstrated, and that the drug carries real trade-offs, including gastrointestinal side effects, rash, and elevated blood sugar. It’s a reminder that “promising” and “practice-changing” aren’t always the same thing at this stage of research — but it represents another step toward matching specific drugs to specific tumor biology rather than treating advanced prostate cancer as a single disease.
A new attempt to make immunotherapy work in prostate cancer
Immunotherapy has transformed treatment for many cancers, but prostate cancer has been notoriously resistant to it — its tumors tend to be immunologically “cold,” meaning they don’t attract much immune attack even with drugs designed to unleash it. A newer approach, bispecific T-cell engagers, is trying to force the issue by physically linking a patient’s own T-cells to PSMA-expressing cancer cells.
An experimental compound called VIR-5500 takes this a step further with a “conditionally activated” design, intended to switch on primarily inside the tumor microenvironment rather than throughout the whole body — an effort to avoid the severe immune overactivation (cytokine release syndrome) that has limited earlier T-cell engager drugs. In early testing among heavily pretreated men with metastatic castration-resistant prostate cancer, the compound produced substantial PSA declines in a meaningful share of patients, with biopsy-confirmed evidence that T-cells were actually infiltrating tumors. It’s early-stage data, but it’s one of the more closely watched signals that immunotherapy might eventually find a foothold in this disease.
Stopping the spread to bone — in the lab, for now
Bone metastasis is one of the most feared complications of advanced prostate cancer, often marking the transition to incurable disease. Preclinical research from VCU Massey Comprehensive Cancer Center, published in Pharmacological Research, identified a small-molecule drug — IVMT-Rx-4 — that blocks a protein called MDA-9/Syntenin, which appears to play a key role in helping prostate tumors establish themselves in bone. In laboratory models, the compound prevented this spread with no observable toxicity.
This work is still preclinical, meaning it hasn’t yet been tested in humans, but it points toward a potential future strategy: intercepting metastasis before it happens, rather than only treating it after the fact.
Can some men safely take a break from treatment?
Finally, an intriguing question is whether men who respond exceptionally well to hormone therapy might eventually pause treatment altogether. The A-DREAM study looked at men with metastatic hormone-sensitive prostate cancer who had strong responses to ADT plus an androgen-blocking drug, and found that 41% of these “exceptional responders” could stop treatment for a period — with testosterone recovering and no treatment needed — for a median of roughly two years before disease activity required restarting therapy.
Researchers were clear that this is not yet standard practice and applies only to a carefully selected subset of patients, but it offers real data for a conversation many patients want to have: does effective treatment always have to be continuous?
The bigger picture
These five threads — perioperative drug intensification, biomarker-matched therapy, immunotherapy re-engineered for a “cold” tumor, metastasis prevention research, and treatment de-escalation — reflect where prostate cancer research is heading: toward more individualized decisions based on a tumor’s specific biology and a patient’s specific response, rather than uniform protocols applied to everyone with a given stage of disease.
Much of this remains investigational or applicable only to specific patient subgroups. Anyone considering how this research might apply to their own diagnosis should raise it directly with their oncologist or urologist.
This article summarizes research presented at the 2026 ASCO Annual Meeting and published research from Massey Cancer Center. It is intended for general information and is not medical advice.